0001127602-19-008415.txt : 20190226
0001127602-19-008415.hdr.sgml : 20190226
20190226170919
ACCESSION NUMBER: 0001127602-19-008415
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190222
FILED AS OF DATE: 20190226
DATE AS OF CHANGE: 20190226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALEXANDER SUSAN H
CENTRAL INDEX KEY: 0001263839
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19311
FILM NUMBER: 19634417
MAIL ADDRESS:
STREET 1: C/O BIOGEN IDEC INC.
STREET 2: 14 CAMBRIDGE CENTER
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOGEN INC.
CENTRAL INDEX KEY: 0000875045
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330112644
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 225 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 7814642000
MAIL ADDRESS:
STREET 1: 225 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: BIOGEN IDEC INC.
DATE OF NAME CHANGE: 20070427
FORMER COMPANY:
FORMER CONFORMED NAME: BIOGEN IDEC INC
DATE OF NAME CHANGE: 20031112
FORMER COMPANY:
FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE
DATE OF NAME CHANGE: 19970530
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2019-02-22
0000875045
BIOGEN INC.
BIIB
0001263839
ALEXANDER SUSAN H
BIOGEN INC.
225 BINNEY STREET
CAMBRIDGE
MA
02142
1
EVP Chief Legal Officer & Sec.
Common Stock
2019-02-22
4
M
0
1663
0
A
29690
D
Common Stock
2019-02-22
4
M
0
6395
48.52
A
36085
D
Common Stock
2019-02-22
4
F
0
3370
325.33
D
32715
D
Common Stock
2019-02-22
4
F
0
739
325.33
D
31976
D
Restricted Stock Unit
0
2019-02-22
4
M
0
1663
0
D
2019-02-22
Common Stock
1663
819
D
Restricted Stock Unit
0
2019-02-22
4
J
0
819
0
D
2019-02-22
Common Stock
819
0
D
Stock Option (Right to Buy)
49.65
2019-02-22
4
M
0
6395
D
2019-02-24
Common Stock
6395
0
D
The stock option was automatically exercised on a net share settlement basis immediately before its expiration, in accordance with its terms. The Company delivered to the reporting person the number of shares underlying the stock option less the number of shares having a Fair Market Value on the date of such exercise equal to (i) the aggregate exercise price for the stock option and (ii) the amount necessary to satisfy any federal, state and local withholding taxes related to such exercise.
This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017.
The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
The stock options become exercisable in four (4) equal annual installments commencing one year after the grant date of 02/24/09.
/s/ Suzanne Murray, Attorney in Fact for Susan Alexander
2019-02-26